XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current assets    
Cash $ 93,217 $ 401,803
Prepaid expenses and other current assets 909,994 764,964
Total current assets 1,003,211 1,166,767
Other assets 866,481
Total Assets 1,003,211 2,033,248
Current liabilities    
Accounts payable 1,801,333 2,222,983
Accrued expenses and other current liabilities 819,015 560,006
Warrant liabilities 187,900 54,600
Convertible debt - related party 1,022,869 1,299,216
Derivative liabilities - related party 693,782
Total current liabilities 4,524,899 4,136,805
Commitments and Contingencies (Note 10)
Qualigen Therapeutics, Inc. stockholders’ equity (deficit):    
Common stock, $0.001 par value; 225,000,000 shares authorized; 6,500,663 and 5,362,128 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively 44,400 43,262
Additional paid-in capital 115,269,047 114,655,565
Accumulated deficit (118,835,135) (116,802,384)
Total Stockholders’ Deficit (3,521,688) (2,103,557)
Total Liabilities & Stockholders’ Deficit $ 1,003,211 $ 2,033,248